Last reviewed · How we verify
NCT07412444: EvoLiveR
EVOO and Metabolic Liver Health in MASLD
NA trial testing Oil Supplementation - 3 tablespoons of oil in MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease in 60 participants. Not yet recruiting.
1 April 2027
Quick facts
| Lead sponsor | Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 April 2026 |
| Primary completion | 1 April 2027 |
| Estimated completion | 1 April 2028 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Oil Supplementation - 3 tablespoons of oil
- 9 Tablespoons of Oil
Conditions studied
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease — all drugs for MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease →
- Overweight — all drugs for Overweight →
Sponsor
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Who can join
Adults 18 to 65, any sex, with MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease or Overweight. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
MASLD is currently one of the most common chronic non-communicable diseases and the leading cause of liver-related mortality and morbidity, with a rising prevalence worldwide, especially in the presence of obesity, diabetes, and other cardio-metabolic risk factors. Lifestyle modification, particularly through the Mediterranean Diet, is the first-line intervention, and extra virgin olive oil is a key component thanks to its monounsaturated fatty acids and bioactive compounds with anti-inflammatory and antioxidant effects. Several studies indicate that extra virgin olive oil supplementation, especially within a Mediterranean Diet pattern, reduces hepatic steatosis, improves inflammation, oxidative stress, and glucose and lipid profiles, and may promote weight loss and reduction of fat mass, also through potential effects on the gut microbiota. EFSA recognizes protective effects with a daily intake of at least 20 g of extra virgin olive oil, but it is still unclear whether this amount is optimal for individuals with MASLD, particularly those who are overweight or obese
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07412444
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Currently open trials in the same condition.
- NCT07270601 — Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis · NA · recruiting
- NCT07097506 — Effect of Ketone Esters on Liver Fat Content and Metabolic Function · Phase 2 · recruiting
- NCT07090083 — Pediatric Metabolic Dysfunction-associated Steatotic Liver Disease and Food Insecurity · recruiting
- NCT07298213 — Corazones Unidos Study · NA · recruiting
- NCT07093346 — The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patient · NA · recruiting
Other Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis trials
Trials by the same sponsor.
- NCT07497789 — SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases · not yet recruiting
- NCT07153458 — Identification of New Non-invasive, Predictive, and Diagnostic Biomarkers for Colorectal Cancer · recruiting
- NCT06931925 — Recall of a Cohort of Subjects in the Mediterranean Area. Monitoring of Liver Diseases (NUTRIHEP 3). · not yet recruiting
- NCT06830317 — Study on the Efficacy of Endoscopic Radiofrequency Treatment in Reducing the Need for Blood Transfusions in GAVE · not yet recruiting
- NCT06615817 — Intermittent Fasting, Mediterranean Diet and NAFLD · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07412444 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
- Last refreshed: 19 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07412444.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing